Connect with us

BenzingaEditorial

7 Telehealth Stocks Paving the way Towards Digitalized Healthcare

Published

on

Telemedicine stock news

Even when the acute phase of the crisis has passed, this pandemic will leave a lasting impact. But telehealth stocks are among the lucky ones to be on the winning side. If we learned anything from this pandemic, it is the value of healthcare. The virus exposed many gaps in the current healthcare system, to say the least. And telemedicine is a big part of the solution.  By digitalizing healthcare services as much as possible, we can reduce strain on the system, lower costs and increase access for patients with mobility issues.

An emerging industry

There aren’t many names when it comes to pure telehealth stocks as companies are just entering the arena. But don’t fear, there are a bunch of quality combinations of healthcare and technology stocks that will benefit just as much as telehealth continues to flourish. And these stocks have plenty of growth potential over the next decade:

  • Teladoc Health

COVID-19 made a star out of Teladoc Health (NYSE:TDOC) for a reason. It is ahead of competitors due to a combination of good product, great marketing and first-mover advantage. It has grown its platform capacity by 5x over the past year. Another astounding figure is that it can handle up to 100 million members. So no wonder that the share price has also rocketed up and resulted in a $12 billion market capitalization. Along with a 20x price-to-sales ratio, both being quite abundant for an early-stage growth company that still hasn’t reached profitability, it has a world of potential ahead.

  • Zoom

We know Zoom Video Communications (NASDAQ:ZM) is among those who saw skyrocketing demand from the pandemic. But its telehealth superpowers are still not as well known. Back in 2017, Zoom launched an offering that is pushed as the “first scalable cloud-based video telehealth solution.” It didn’t immediately take off as Teladoc but as video conferencing boomed during the pandemic and health professionals benefited from it. Zoom’s video healthcare solution has the built-in patient privacy protections, remote waiting rooms, remote camera control and support for cameras, digital stethoscopes, just to name a few. Along with signing key clients, such as Moffitt Cancer Center, one cannot afford to follow up on Zoom Video’s progress in telehealth over the coming quarters.

  • Humana – insurance

Did you really think we can speak of healthcare without mentioning insurance? Humana (NYSE:HUM) has been among the very first adopters of virtual doctor visits even before the pandemics. And when COVID-19 swept through the globe, it provided more than 150 different but digitalized health services.

  • Anthem

Anthem (NYSE:ANTM) was just as quick in taking its place at virtual healthcare, entering the field already in 2016. With more than 200 digital kiosks that allow patients access to community resources, telehealth services, video conferences and insurance benefits information, it provides time help in dozens of languages to everyone in need.

  • CVS – drugstores

Moving on to drugstores, CVS (NYSE:CVS) differs greatly with its all-in-one approach from its key rival Walgreens (NASDAQ:WBA) and its namesake pharmacies. It ties together the pharmacy and the insurance plans. Whether it will be profitable is another question as it’s too soon to tell. However, once it realizes its full potential, it could become a massive telehealth player.

  • iRobot – more than vacuum cleaners!

Believe it or not iRobot (NASDAQ:IRBT) also helped create the first telemedicine robot. IRBT, along with parter InTouch, received Food and Drug Administration approval in 2013 for a robot that could facilitate virtual meetings between doctors and patients. Their RP-Vita robot was useful for allowing doctors to collect information, via iPad, when they couldn’t meet with a patient in person. With COVID-19, it seems as a great area to direct research and development funds.

  • Castlight Health- software

Castlight Health (NYSE:CSLT)  is a software company that connects various players in the healthcare space: from doctors all the way to insurance firm. It did stumble under its prior CEO which lead to the company losing major customers, but we all know the value of networking! And new management has delivered improved and strong operating results recently. Although it’s too soon to see if this progress is sustainable, it helped patients identify COVID-19 test locations. Large revenues are usually not the result of such endeavors, but this did show the value of the network it provides.

The benefits of a digitalized healthcare

Adopting virtual medicine should not only reduce costs but more importantly, improve patient outcomes. The pandemic revealed the enormous inefficiencies in the healthcare systems. Whoever removes the red tape will surely score in its top and bottom lines. And even after COVID-19 is is gone, telemedicine has a lot of potential ahead.

This article is not a press release and is contributed by Ivana Popovic who is a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . Ivana Popovic does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com Questions about this release can be send to ivana@iamnewswire.com

BenzingaEditorial

News From The Vaccine World

Published

on

Less than a year before the COVID-19 started its relentless march across the globe Novavax (NASDAQ: NVAX) was facing delisting from the Nasdaq. The 33-year-old Maryland-based pharmaceutical company didn’t have a single approved shot after hundreds of millions of dollars invested in its R&D efforts. Wall Street likes to take bets on unproven biotech such as Moderna Inc (NASDAQ: MRNA), but it can be unforgiving of failure.  Fortunately, Novavax is now on the verge of getting approval in the UK, which will probably be followed by the US. Interim data have shown that its vaccine has an efficacy rate up there with the shots developed by Moderna, BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE), all of which are based on revolutionary mRNA technology. However, Novavax’ candidate s is cheaper and easier to transport and can be stored at room temperature for at least 24 hours. Additionally, the one-shot candidate by Johnson & Johnson (NYSE: JMJ) that can be kept at normal temperatures was granted an emergency use authorization during the weekend.

Merck and Johnson will join forces

Merck & Co Inc (NYSE: MRK) will manufacture the vaccine made by Johnson & Johnson (NYSE: JMJ) under an unusual deal that the Biden administration engineered to boost production of the single-shot ja which has been hampered by manufacturing delays.

The Biden administration helped to engineer the deal between the competitors after J&J, which was, experienced production hold-ups. J&J is the world’s largest healthcare company, but when it comes to vaccines, Merck has the expertise as it is one of the world’s largest vaccine makers with many approved shots.

Sanofi (NASDAQ: SNY) is another large vaccine maker that has fallen behind in the COVID-19 vaccine race and has agreed to help boost supplies of the J&J vaccine in Europe. Last month, it stated it would use its capacity to fill vials.

Novavax has finally stopped gasping for air

The CEO of Novavax, Stanley Erck, stated their candidate is more than 90% effective against the original strain, 86% effective against the U.K. strain and considerably less effective against the South African strain. According to forecasts, Novavax will generate more than $5 billion in revenue this year. As it is applying for approval for it flu shot, it will start studies on combining the Covid-19 and flu vaccine into a single shot later this year.

A story with a happy ending for everyone?

Novavax’s story resembles a Cinderella story as a little company that was on the verge of potentially closing has really been able to play with the big boys in the race for the Covid vaccine. The bottom line is that the US will have enough coronavirus vaccine doses for every adult by the end of May, which is sooner than anticipated, thanks in part to an unusual type of collaboration we didn’t see since World War II between two of the country’s largest drugmakers.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Workhorse and Worksport Both Delivered Good News This Week

Published

on

EV Update

This week began with good news in the EV world. On Monday, electric truck maker Workhorse Group (NASDAQ: WKHS) reported before market open. Its shares bounced 4.7% in midday trading Monday after the electric vehicle maker reported a surprise fourth-quarter net profit despite falling short on sales. A piece of good news were more then welcome after last week’s selloff that plunged as low as 47.5% plunge last Tuesday, after the U.S. Postal Service awarded a contract for delivery trucks exclusively to Oshkosh Corporation (NYSE: OSK), while Workhorse was widely expected to win at least a part of the contract. On Tuesday morning, tonneau-cover manufacturer Worksport (OTC: WKSP) announced it is expanding its capacity to meet increased demand. Worksport announced this morning that it received over US$2.3 Million to date from Exercised Warrants from the recent oversubscribed Regulation A offering.

Workhorse Q4 results

The company reported its net income rose to $280.5 million from $655,000 a year ago, thanks largely to income derived from its investment in Lordstown Motors (NASDAQ: RIDE), an electric pickup startup founded by Workhorse’s former chief executive. The FactSet expected a net loss of $15.1 million. Revenues increased from $3,000 to $652,000, due to a higher volume of produced and delivered trucks, but still came short of FactSet consensus of $1.2 million. According to its Chief Executive, the company is entering the new year in its strongest-ever position, both financially and operationally. With over $200 million of cash on its balance sheet and over 8,000 vehicles in its backlog, it can reliably continue building its multi-year growth plan.

The EV maker is not taking a recent high-profile defeat lying down

The company also revealed it will meet with U.S. Postal Service (USPS) management on Wednesday to discuss the latter’s recent awarding of a 10-year contract that would place Workhorse among top EV manufacturers. With at least 50,000 trucks to be manufactured within a decade, this will be the most dramatic modernization of the USPS fleet in three decades. While the USPS is one of the more financially strapped government entities, cy it’s considered to be an extremely reliable business partner. Following the USPS’s awarding of the contract to Oshkosh, Workhorse issued a press release in which it clearly stated it intends to explore all avenues that are available to non-awarded finalists in a government bidding process. Its odds of getting a second shot could depend on whether President Biden is able to force out the postmaster general who was installed last year by board members appointed by former President Donald Trump.

Worksport is expanding due to increased demand

Innovative pickup truck tonneau cover manufacturer Worksport partnered with Atlis Motor Vehicles and Hercules Electric Vehicles to configure its revolutionary TerraVis solar system for their upcoming electric pickup trucks is expanding further. The company announced on Tuesday morning it is in the final phase of a strategic manufacturing expansion discussions with a few Tier-1 and Tier-2 OEM manufacturing power houses in Canada. The company aims to expand its manufacturing into North American state-of-the-art facilities with 20,000 to 50,000 square feet of operating space to meet its recent U.S.-based Private Label customer growth.  Considering the company was awarded its first trademark in China, this is only the beginning of Worksport’s growth story, not to mention the company is also expanding outside the pickup truck market to the consumer market by extending its solar fusion line with mobile TerraVis COR™ system that can be used independently and recharged via solar or A/C power. These discussions involve logistics to ensure scalability in the manufacturing processes. The expansion will give the company control over capital expenses, greatly reducing risks of overextending its financials during periods of intense demand while building its major Automotive, Freight & Transport, Marine, and Rail ecosystems. With its CEO Steven Rossi at the helm, Workhorse is going all in to exceed customer expectations in terms of quality, innovation, convenience and last but not least, affordability.

Outlook

Workhorse aims to increase production to three trucks a day by the end of this month and reach a daily output of 10 trucks by the end of June. Worksport is aiming to become a Tier 1 OEM manufacturer of solar-powered tonneau covers for electric makers and by the looks of it, it’s well on track, especially as it successfully closed its $4 million Regulation A offering at the beginning February well ahead of the scheduled closing due in November 2021. Demand that is fueling Worksport to rapid growth is key, which is why Workhorse isn’t willing to take USPS’ no for answer.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Target Hits The Bull’s Eye With Yet Another Quarter

Published

on

Some of its biggest peers such as Macy’s Inc (NYSE: M) and Best Buy Co.Inc (NYSE: BBY) came out with improving fourth quarter sales and profit outlook as a tiny bit of normalcy begins to return to consumer spending, but now it’s Target’s (NYSE: TGT) turn in the spotlight. Earnings topped estimates as sales rose 21%, boosted by a surge of post-holiday shoppers that cashed in stimulus checks during an unusually strong period for the industry as a government report revealed sales increased 5.3% in January. As of Monday’s close, Target shares have risen nearly 81% over the past year, bringing the company’s market value to $93.19 billion.

Q4

For the fiscal fourth quarter ended on January 30th, revenue rose 21% to $28.34 billion from $23.4 billion last year, higher than analysts’ expectations of $27.48 billion. Comparable sales, a key metric that tracks sales at stores open at least 13 months and online, went up 20.5% compared to the prior year as digital comparable sales rose by 118% YoY. After strong holiday sales, online sales gained even more momentum as Americans cashed in their $600 stimulus checks in January. As impressive as they are, both metrics show deceleration in terms of growth rates versus the third quarter. In mid-January, Target reported that sales grew 17% during the holidays, which is a slight slowdown from the third quarter’s 21% spike, but it is still a lot better compared to the 9% that Walmart (NYSE: WMT) experienced.

Profit margin was 26.80% and the operating margin amounted to 6.50%. Net income rose 66% to $1.38 billion, or $2.73 per share, increasing from last year quarter’s $834 million or $1.63 per share. Excluding items, Target earned $2.67 per share, exceeding Refinitiv’s average expectation of $2.54.

New customers and more purchases

Target has attracted new customers and inspired more purchases with its e-commerce offerings and wide range of merchandise, from cereal to workout pants, as competitors like Kohl’s Corporation (NYSE: KSS) were forced to temporarily close stores due to the pandemic. Citing internal and third-party research, Target estimates it gained about $9 billion in market share during the fiscal year. Customers shopped more frequently with Target and bought more when they did during the holiday quarter thanks to its e-commerce offerings and wide range of merchandise.

A variety of approaches to shopping

By offering different multiple channels, Target is strengthening customer loyalty. Same-day services saw sales grow by 212% and curbside pickup service sales grew by more than 500% during the quarter. On average, customers who shop in both in stores and online spend nearly four times more than those who shop only in stores and nearly ten times more than those who only shops online.

Fiscal 2020

2020 sales grew by more than $15 billion which is greater than Target’s combined sales growth of the last 11 years. Comparable sales grew 19.3%, reflecting 7.2% growth in store comparable sales, and 145% growth in digital comparable sales.

Target’s 2020 stock price rally is largely owed to improved margins. While the competitive holiday season usually pressures this figure, this wasn’t so much of an issue this year as shoppers happily paid the full price for more convenient and faster fulfillment options, including premium merchandise.

Another quarter in which Target hit the bull’s eye is in the books ended a record year which is not a pandemic-related blip but the payoff of its long-term business strategy. Record growth in 2020 was a result of many years of investment to build a durable, scalable and sustainable business model that enabled the big box retailer to capitalize on the opportunity that was provided by the pandemic.

Outlook

Target remains extra cautious in the face of continued uncertainty as the pandemic has made it too difficult to predict consumer patterns. No sales or EPS guidance for fiscal 2021 were provided. Although shoppers are still cautious, Target is also seeing hopeful consumers who are looking forward to a post-pandemic life, expecting to see shoppers browsing aisles and returning to buying items such as apparel for work or going out as well as new luggage. To find a way to hold on to customer’s wallets after vaccines kick in, the big box retailer plans to invest about $4 billion per year over the next several years to open new stores, upgrade existing ones and enhance its ability to quickly fulfill online orders.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Advertisement

TRENDING

Advertisement

Submit an Article

Send us your details and the subject of your article and an IAM editor will be in touch with you shortly

Trending